Syntrix

Illumina has asked a federal court to dismiss a six-month-old trademark infringement lawsuit against Illumavista Biosciences following an apparent out-of-court settlement.

While Syntrix Biosystems may have played a role in developing foundational microarray technology, the company does not intend to use a large, recently awarded royalty payment from Illumina to expand its presence in the array market.

This story was originally posted on March 15.

NEW YORK (GenomeWeb News) – A federal court jury has ordered Illumina to pay $96 million in damages to Syntrix Biosystems in a patent infringement case.

A jury is considering whether Illumina has infringed the intellectual property of Syntrix, a company with whom the San Diego vendor discussed a potential business relationship more than a decade ago.

Illumina denies that its arrays infringe Syntrix's IP and has asked the court to declare that the patent at the heart of the case is invalid and that the suit be dismissed with prejudice.

In the suit, Syntrix alleges that Illumina has based its array products on technology developed originally by Syntrix and provided confidentially to Illumina a decade ago while the two firms were discussing a possible business relationship.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.